Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Piper Sandler Initiates Coverage of Gilead Sciences With Neutral Rating, $77 Price Target

11/18/2021 | 04:17pm EST


ę MT Newswires 2021
All news about GILEAD SCIENCES, INC.
01/19GLOBAL MARKETS LIVE : Bank of America, ASML, Intel, Oracle, Burberry...
01/19WALL STREET STOCK EXCHANGE : Temporary respite for the Nasdaq
01/19MARKETSCREENER’S WORLD PRESS REVIEW : January 19, 2022
01/19ANALYST RECOMMENDATIONS : Activision Blizzard, Chevron, Exxon Mobil, Gilead, Goldman Sachs..
01/19GILEAD SCIENCES : Announces Actions to Remove Counterfeit HIV Medications from U.S. Supply..
PU
01/18Gilead says counterfeit HIV drugs ended up with patients
RE
01/18Health Care Down Amid Flight From Cyclical Sectors -- Health Care Roundup
DJ
01/18Gilead Sciences to Release Fourth Quarter & Full Year 2021 Financial Results on Tuesday..
BU
01/18Morgan Stanley Lowers Price Target for Gilead Sciences to $72 From $74, Maintains Equal..
MT
01/18Gilead says counterfeiting network sold $250 mln worth of its HIV drugs
RE
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 26 576 M - -
Net income 2021 7 176 M - -
Net Debt 2021 22 428 M - -
P/E ratio 2021 12,0x
Yield 2021 4,10%
Capitalization 85 060 M 85 060 M -
EV / Sales 2021 4,04x
EV / Sales 2022 4,20x
Nbr of Employees 13 600
Free-Float 99,9%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Last Close Price 69,07 $
Average target price 75,96 $
Spread / Average Target 9,97%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.-4.88%86 640
REGENERON PHARMACEUTICALS-2.12%64 627
VERTEX PHARMACEUTICALS5.12%58 692
WUXI APPTEC CO., LTD.-6.39%51 406
BIONTECH SE-37.29%39 044
BEIGENE, LTD.-12.58%24 335